Product/Composition:- | Ritonavir & Lopinavir |
---|---|
Strength:- | Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL |
Form:- | Tablet and Oral Solution |
Reference Brands:- | Kaletra(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lopinavir & Ritonavir Tablets (Kaletra®) combine two protease inhibitors for HIV treatment. Available in 200/50 mg strength, they are sourced via PharmaB2B platforms from WHO-GMP-approved manufacturers. Perfect for bulk procurement, tenders, and public health programs ensuring global access to essential HIV medicines.
Lopinavir & Ritonavir Tablets, widely marketed as Kaletra®, are a fixed-dose combination of two protease inhibitors used in the treatment of HIV-1 infection. Each tablet typically contains Lopinavir 200 mg and Ritonavir 50 mg, with Ritonavir boosting the effectiveness of Lopinavir. This antiretroviral combination remains vital in HIV care, especially in resource-limited settings and global treatment programs. PharmaB2B platforms connect global buyers, NGOs, and procurement agencies with WHO-GMP and USFDA-approved manufacturers offering bulk supply at competitive rates. Ideal for tenders and institutional supply, this therapy supports consistent, affordable access to HIV medications worldwide.